{"id":"W7024029596","doi":"","title":"Protalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corporate Update","year":2017,"lang":"en","type":"other","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Risk management; Payment; Key (lock)","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006053206,0.00104926,0.0008372464,0.003504041,0.001106093,0.009396468,0.001917014,0.004032744,0.2399232],"category_scores_gemma":[0.01179076,0.0004783713,0.0009623849,0.001693732,0.00100898,0.003037299,0.002129165,0.004023909,0.2216579],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002817445,"about_ca_system_score_gemma":0.01008688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003234263,"about_ca_topic_score_gemma":0.005259139,"domain_scores_codex":[0.9949255,0.0003270296,0.000227473,0.0002053435,0.003789761,0.0005248709],"domain_scores_gemma":[0.982624,0.001507641,0.001099359,0.001048188,0.0102176,0.003503215],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007758493,0.0001297306,0.000266327,0.00009779177,0.000005168944,0.00006416871,0.00001265893,0.00005893682,0.0003255872,0.001440803,0.9303315,0.06718975],"study_design_scores_gemma":[0.00003270845,0.00003724356,0.0003988835,0.000110109,0.000006064492,0.00008598638,0.00001934313,0.0001435972,0.0007427184,0.000680029,0.9977366,0.000006653545],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.002719508,0.007614111,0.003501681,0.04377193,0.03812967,0.0005852873,0.01142659,0.004186146,0.8880652],"genre_scores_gemma":[0.006033852,0.0062158,0.00191976,0.008834627,0.008476318,0.0001881421,0.01116349,0.001460435,0.9557076],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.2399232,"threshold_uncertainty_score":0.8026232,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04871906888237188,"score_gpt":0.3090232978968216,"score_spread":0.2603042290144497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}